...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Effectiveness and Safety of?Ginkgo biloba, Vinpocetine and Piracetam as a Single Agent and Fixed Dose Combination in Patients with Subjective Tinnitus
【24h】

Effectiveness and Safety of?Ginkgo biloba, Vinpocetine and Piracetam as a Single Agent and Fixed Dose Combination in Patients with Subjective Tinnitus

机译:ΔBiloba,vinpocetine和piracetam作为主体耳鸣患者的单一药剂和固定剂量组合的有效性和安全性

获取原文

摘要

Owing to the lack of any standard treatment, subjective tinnitus can be debilitating, manifesting a varied population response to tinnitus management.There is, therefore, an unmet need to optimise the existing treatment options and generate data to help physicians provide the best possible care for individual patients.Aim: To compare the effectiveness and safety of Ginkgo biloba, vinpocetine, and piracetam as a single agent and their Fixed Dose Combination (FDC) in patients with subjective tinnitus.Materials and Methods: Patients with complaints of subjective tinnitus were enrolled in this longitudinal cohort, single centre study which was conducted at Outpatient Clinic of the ENT Department of Justice KS Hegde Charitable Hospital, Karnataka, India.Patients received one of the five treatments, oral route, three times a day, {group 1: Ginkgo biloba (40 mg); group 2: vinpocetine (5 mg); group 3: piracetam (400 mg); group 4: FDC of Ginkgo biloba (60 mg) and piracetam (400 mg); group 5: FDC of Ginkgo biloba (60 mg), piracetam (800 mg) and vinpocetine (5 mg)} and were followed-up for six weeks using a modified version of Tinnitus Handicap Inventory (THI) and Visual Analogue Scale (VAS), before and after the treatment.Data for safety were also recorded.The association between each attribute and the presence of tinnitus was assessed through chi-square tests.Results: A total of 130 out of 149 enrolled patients completed the study.All the groups showed significant improvement in the severity of symptoms at the end of six weeks as assessed by the modified THI and VAS scores.The improvement was found to be better in group 5 than in other groups, which was evident from the percentage improvement at the end of the treatment compared to other groups.No adverse drug reactions were associated with any of the treatment groups.Conclusion: Though all the drugs were found to be effective and safe in reducing the intensity of subjective tinnitus, FDC of Ginkgo biloba-piracetam-vinpocetine may be considered a better alternative than Ginkgo biloba-piracetam combination and Ginkgo biloba, piracetam, or vinpocetine as single agents.
机译:由于缺乏任何标准治疗,主观耳鸣可以衰弱,表现出各种人口对耳鸣管理的反应。因此,未满足的需要优化现有的治疗方案并生成数据,以帮助医生提供最佳照顾个人患者:将Ginkgo Biloba,Vinpocetine和Piracetam作为单一代理人的有效性和安全性和其固定剂量组合(FDC)的主观耳鸣。主观耳鸣患者入学这种纵向队列,单一中心研究,在印度Ks Hegde慈善医院的Ent justice Ks Hegde慈善医院的门诊诊所进行.Patiants,患有五个治疗,口头路线,三次,{Group 1:银杏毕洛波巴(40毫克);第2组:Vinpocetine(5毫克);第3组:Piracetam(400毫克);第4组:银杏叶(60 mg)和Piracetam(400毫克)的FDC;第5组:Ginkgo Biloba(60 mg),皮拉酮(800mg)和vinpocetine(5 mg)}的FDC,并使用修改版的耳鸣障碍库存(THI)和视觉模拟量表(VAS)进行随访六周,在治疗之前和之后。还记录了安全性。通过Chi-Square Tests评估每个属性和耳鸣的存在的关联。结果:149名注册患者中共有130名已完成该研究。所有这些群体通过改性的THI和VAS评分评估,六周末期的症状严重程度显着改善。在第5组中发现改善比其他群体更好,这是从末尾的改善百分比改善明显治疗与其他群体相比。不良药物反应与任何治疗组有关。结论:虽然发现所有药物都是有效和安全的,但在降低Ginkgo Biloba-piraceta的FDC的主观耳鸣强度M-VINPOCetine可以被认为是与银杏叶吡酰胺组合和银杏叶,PiLacetam或Vinpocetine作为单一剂的更好的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号